N-[(1,1-二甲基乙氧基)羰基]-L-缬氨酰-L-脯氨酸 | 23361-28-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[(1,1-二甲基乙氧基)羰基]-L-缬氨酰-L-脯氨酸
• 中文别名: 叔丁氧羰基-缬氨酰-脯氨酸
• 英文名称: N-(tert-butyloxycarbonyl)-L-valyl-L-proline
• 英文别名: (2S)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-methylbutanoyl]pyrrolidine-2-carboxylic acid；(tert-butoxycarbonyl)-L-valyl-L-proline；N-tert-butoxycarbonyl-L-valyl-L-proline；N-(t-butoxycarbonyl)-L-valyl-L-proline；(N-Boc-L-valine)-L-proline；Boc-Val-Pro-OH；(2S)-1-[(2S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]pyrrolidine-2-carboxylic acid
• CAS: 23361-28-6
• 化学式: C₁₅H₂₆N₂O₅
• mdl: MFCD00076997
• 分子量: 314.382
• InChiKey: VUYWLCHFKCFCNH-QWRGUYRKSA-N

物化性质

• 熔点：
  137-138 °C
• 沸点：
  503.2±45.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，存于干燥密封条件下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-val-pro-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-val-pro-oh
CAS number: 23361-28-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H26N2O5
Molecular weight: 314.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-[(1,1-二甲基乙氧基)羰基]-L-缬氨酰-L-脯氨酸 在 N-甲基吗啉 、 盐酸 、 sodium hydroxide 、 1-羟基苯并三唑 、 戴斯-马丁氧化剂 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Hepatitis C virus NS3-4A serine protease inhibitors: SAR of moiety with improved potency

  摘要：

  We have discovered that introduction of appropriate amino acid derivatives at P'2 position improved the binding potency of P3-capped alpha-ketoamide inhibitors of HCV NS3 serine protease. X-ray crystal structure of one of the inhibitors (43) bound to the protease revealed the importance of the P'2 moiety.

  DOI：

  10.1016/j.bmcl.2005.06.091
• 作为产物：
  描述：

  Boc-Val-Pro-OBzl 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以94%的产率得到N-[(1,1-二甲基乙氧基)羰基]-L-缬氨酰-L-脯氨酸
  参考文献：
  名称：

  2, 3-二氯苯基哌嗪二肽的尿素和硫脲衍生物对脲酶活性的抑制

  摘要：

  目的：酶抑制研究仍然是药物研究的一个重要领域，因为这些研究导致发现了用于各种生理条件的药物。为了寻找新型脲酶抑制剂，合成了四种二肽，与 2,3-二氯苯基哌嗪类似物缀合并转化为尿素/硫脲衍生物。方法：通过溶液相法合成肽，并使用 1-乙基-3-（3-二甲基氨基丙基）碳二亚胺（EDCI）/羟基苯并三唑（HOBt）作为偶联剂和 N -甲基吗啉（NMM）作为碱。使用三氟乙酸 (TFA) 去除叔丁氧羰基 (Boc) 基团，用 NMM 中和并分别使用取代的异氰酸苯酯和异硫氰酸酯转化为尿素和硫脲衍生物。结果：大多数合成的类似物被发现是脲酶酶活性的良好抑制剂。在间位或对位具有 F 和 Cl 取代基的硫脲的缀合物显示出主要的脲酶抑制活性。类似物 23 的效力比参考标准品 21.0±0.11 µM 强近 10 倍 (2 µM)。结论：报告的活性与一些文献报道的脲酶抑制剂相关，发现我们的化合物 23 比现有化合物更有效。在间位或对位具有

  DOI：

  10.22159/ijpps.2017v9i9.19425

文献信息

• [EN] STAT DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2021188696A1

  公开（公告）日：2021-09-23

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• Synthesis of a Novel <i>cis</i>-Proline-Derived Cyclic Type VI β-Turn Mimic via Ring-Closing Metathesis
  作者：Anima Boruah、I. Nageshwar Rao、Jyoti Prokash Nandy、S. Kiran Kumar、A. C. Kunwar、Javed Iqbal

  DOI：10.1021/jo020618m

  日期：2003.6.1

  A cis-proline derived cyclic mimic of a type VI beta-turn is synthesized via a ring-closing metathesis reaction. The solution NMR conformational study indicates that the major conformer of the cyclic peptide adopts a type VIa beta-turn in CDCl(3) and a type VIb beta-turn in DMSO-d(6).

  经由闭环易位反应合成了顺式脯氨酸衍生的VI型β-转角的环状模拟物。溶液NMR构象研究表明，环肽的主要构象异构体在CDCl（3）中采用VIa型β-转角，而在DMSO-d（6）中采用VIb型β-转角。
• Synthesis of Cyclic Peptidomimetics via a Pd-Catalyzed Macroamination Reaction
  作者：Brett A. Hopkins、Graham F. Smith、Nunzio Sciammetta

  DOI：10.1021/acs.orglett.6b01961

  日期：2016.8.19

  A new method to access cyclic peptidomimetics via a Pd-catalyzed macroamination reaction is presented. Natural amino acid amines are revealed as proficient coupling partners in these transformations. With a commercially available CPhos G3 catalyst system and substrates bearing diverse amino acid and aryl halide backbones, the unique head to side-chain (or side-chain mimic) macrocycles are afforded

  提出了一种新的通过Pd催化的巨胺化反应获得环状拟肽的方法。天然氨基酸胺被揭示为这些转化中熟练的偶联伴侣。使用可商购的CPhos G3催化剂体系和带有多种氨基酸和卤代芳基骨架的底物，可提供独特的头到侧链（或侧链模拟物）大环，环尺寸为11至23个成员，产率高达84％ 。
• Inhibitors of Tripeptidyl Peptidase II. 2. Generation of the First Novel Lead Inhibitor of Cholecystokinin-8-Inactivating Peptidase:  A Strategy for the Design of Peptidase Inhibitors
  作者：C. Robin Ganellin、Paul B. Bishop、Ramesh B. Bambal、Suzanne M. T. Chan、James K. Law、Benoit Marabout、Pratibha Mehta Luthra、Andrew N. J. Moore、Olivier Peschard、Pierre Bourgeat、Christiane Rose、Froylan Vargas、Jean-Charles Schwartz

  DOI：10.1021/jm990226g

  日期：2000.2.1

  fluorimetric assay based on the hydrolysis of the artificial substrate Ala-Ala-Phe-amidomethylcoumarin. A series of di- and tripeptides having various alkyl or aryl side chains was studied to determine the accessible volume for binding and to probe the potential for hydrophobic interactions. From this initial study the tripeptides Ile-Pro-Ile-OH (K(i) = 1 microM) and Ala-Pro-Ala-OH (K(i) = 3 microM) and dipeptide

  失活胆囊收缩素8（CCK-8）的肽酶是一种丝氨酸肽酶，已证明是三肽基肽酶II的膜结合同工型（EC 3.4.14.10）。它在Met-Gly键处裂解神经递质CCK-8硫酸盐，得到Asp-Tyr（SO（3）H）-Met-OH + Gly-Trp-Met-Asp-Phe-NH（2）。为了寻找该肽酶的可逆抑制剂，使用基于人工底物Ala-Ala-Phe-酰胺基甲基香豆素水解的荧光分析法来表征酶促结合亚位点。对具有各种烷基或芳基侧链的一系列二肽和三肽进行了研究，以确定可结合的体积并探讨疏水相互作用的可能性。根据这项初步研究，三肽Ile-Pro-Ile-OH（K（i）= 1 microM）和Ala-Pro-Ala-OH（K（i）= 3 microM）和二肽酰胺Val-Nvl-NHBu（K（ i）= 3 microM）作为线索出现。这些结构的比较导致Val-Pro-NHBu（K（i）= 0.57 micr
• Inhibition of Human Neutrophil Elastase. 3. An Orally Active Enol Acetate Prodrug
  作者：Joseph P. Burkhart、Jack R. Koehl、Shujaath Mehdi、Sherrie L. Durham、Michael J. Janusz、Edward W. Huber、Michael R. Angelastro、Shyam Sunder、William A. Metz

  DOI：10.1021/jm00002a003

  日期：1995.1

  vitro studies, in the presence of added esterase, and 19F NMR studies, in biological media, indicated that the E-enol acetate derivatives should act as prodrugs in vivo. The ED50 value for (E)-N-[4-(4-morpholinylcarbonyl)benzoyl]-L-valyl-N-[2- (acetyloxy)-3,3,4,4,4-pentafluoro-1-(1-methylethyl)-1-buteny l]-L-prolinamide (20), when administered orally in the hamster lung hemorrhage model, was 9 mg/kg

  N- [4-（4-吗啉基羰基）苯甲酰基] -L-戊基-N- [3,3,4,4,4-戊五氟-1-（1-甲基乙基）-2-氧丁基] -L的几种类似物合成了其中已消除了P1残基手性中心的β-脯氨酰胺（1），并作为人嗜中性粒细胞弹性蛋白酶（HNE）的抑制剂进行了测试。在这项工作的过程中观察到的结果导致开发了一种从HNE抑制剂（在P1处含有差向异构体的混合物）一步一步，立体选择性地合成E-烯醇乙酸酯衍生物的方法。在存在酯酶的情况下进行的体外研究以及在生物介质中的19 F NMR研究表明，乙酸烯醇酯衍生物应在体内充当前药。（E）-N- [4-（4-吗啉基羰基）苯甲酰基] -L-戊基-N- [2-（乙酰氧基）-3,3,4,4,4-五氟-1-（1）的ED50值-甲基乙基）-1-丁烯基1] -L-脯氨酰胺（20），